Zanzinger Kai, Schellack Carola, Nausch Norman, Cerwenka Adelheid
German Cancer Research Centre (DKFZ), Innate Immunity, 69120 Heidelberg, Germany.
Immunology. 2009 Oct;128(2):185-95. doi: 10.1111/j.1365-2567.2009.03091.x.
Triggering receptor expressed on myeloid cells 1 (TREM-1) is an activating receptor involved in inflammatory diseases and septic shock. The TREM-1 ligand(s) (TREM-1L) have not yet been identified. In this study, we performed a detailed analysis of the expression of mouse TREM-1 and its ligand(s). Our results demonstrate that TREM-1 is expressed on bone-marrow-derived dendritic cells (BMDC). On bone-marrow-derived macrophages (BMM) its expression is induced in vitro after stimulation by granulocyte-macrophage colony-stimulating factor, interleukin-3 or by myeloid differentiation primary response gene 88 (MyD88)-dependent Toll-like receptor (TLR) ligands. Under steady-state conditions mouse TREM-1 is detectable on a Gr-1(-) F4/80(+) monocyte subpopulation bearing markers of resident monocytes, but not on Gr-1(+) F4/80(+) inflammatory monocytes. During lipopolysaccharide (LPS)-induced endotoxaemia TREM-1 was also up-regulated on inflammatory Gr-1(+) F4/80(+) cells in vivo. In tumour-bearing mice, TREM-1 was up-regulated on Gr-1(+) F4/80(+) monocytes, which phenotypically and functionally resembled mononuclear myeloid-derived suppressor cells. Using a soluble TREM-1 fusion protein, we demonstrate that after intravenous injection of LPS TREM-1L was induced on Gr-1(+) granulocytes and monocytes but not on other cell populations in peripheral blood. This up-regulation on granulocytes was directly mediated by TLR ligands and required the adapter protein MyD88. In contrast to human, mouse platelets expressed TREM-1L neither under steady-state conditions nor after LPS injection in vivo. Our study reveals differential regulation of TREM-1 expression on mouse monocyte subpopulations and improves our understanding of the biological role of TREM-1 during disease.
髓系细胞触发受体1(TREM-1)是一种参与炎症性疾病和脓毒性休克的激活受体。TREM-1配体(TREM-1L)尚未被鉴定出来。在本研究中,我们对小鼠TREM-1及其配体的表达进行了详细分析。我们的结果表明,TREM-1在骨髓来源的树突状细胞(BMDC)上表达。在骨髓来源的巨噬细胞(BMM)上,其表达在体外受到粒细胞-巨噬细胞集落刺激因子、白细胞介素-3或髓系分化初级反应基因88(MyD88)依赖的Toll样受体(TLR)配体刺激后被诱导。在稳态条件下,小鼠TREM-1在带有常驻单核细胞标志物的Gr-1(-)F4/80(+)单核细胞亚群上可检测到,但在Gr-1(+)F4/80(+)炎性单核细胞上未检测到。在脂多糖(LPS)诱导的内毒素血症期间,TREM-1在体内的炎性Gr-1(+)F4/80(+)细胞上也上调。在荷瘤小鼠中,TREM-1在Gr-1(+)F4/80(+)单核细胞上上调,这些单核细胞在表型和功能上类似于单核髓系来源的抑制细胞。使用可溶性TREM-1融合蛋白,我们证明静脉注射LPS后,TREM-1L在Gr-1(+)粒细胞和单核细胞上被诱导,但在外周血的其他细胞群体上未被诱导。粒细胞上的这种上调是由TLR配体直接介导的,并且需要衔接蛋白MyD88。与人类不同,小鼠血小板在稳态条件下或体内注射LPS后均不表达TREM-1L。我们的研究揭示了小鼠单核细胞亚群上TREM-1表达的差异调节,并增进了我们对TREM-1在疾病期间生物学作用的理解。